Cholesterol crystal embolization: an atherosclerotic disease with frequent and varied cutaneous manifestations.
In this paper the basic pathogenesis of cholesterol crystal embolization (CCE) is described, its clinical characteristics are presented and diagnosis and therapy are discussed. The main focus will be on the cutaneous manifestations; however, considering that CCE is a systemic illness, findings in other organs will also be highlighted, particularly the commonly involved renal and gastrointestinal systems.
Donohue
K G
KG
Department of Dermatology and Skin Surgery, Roger Williams Medical Center, Providence, Rhode Island, USA.
Saap
L
L
Falanga
V
V
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000175:diagnosis* / Q000401:mortality / Q000503:physiopathology; D001707:Biopsy, Needle; D002423:Cause of Death; D003460:Crystallization; D017700:Embolism, Cholesterol / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality*; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007150:Immunohistochemistry; D008297:Male; D011379:Prognosis; D012307:Risk Factors; D012720:Severity of Illness Index; D012871:Skin Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D015996:Survival Rate; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000960:Hypolipidemic Agents